These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32300820)

  • 1. [Neoadjuvant and adjuvant treatment of pancreatic cancer].
    Springfeld C; Hackert T; Jäger D; Büchler MW; Neoptolemos JP
    Chirurg; 2020 Aug; 91(8):636-641. PubMed ID: 32300820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial.
    van Dam JL; Verkolf EMM; Dekker EN; Bonsing BA; Bratlie SO; Brosens LAA; Busch OR; van Driel LMJW; van Eijck CHJ; Feshtali S; Ghorbani P; de Groot DJA; de Groot JWB; Haberkorn BCM; de Hingh IH; van der Holt B; Karsten TM; van der Kolk MB; Labori KJ; Liem MSL; Loosveld OJL; Molenaar IQ; Polée MB; van Santvoort HC; de Vos-Geelen J; Wumkes ML; van Tienhoven G; Homs MYV; Besselink MG; Wilmink JW; Groot Koerkamp B;
    BMC Cancer; 2023 Aug; 23(1):728. PubMed ID: 37550634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer].
    Scheufele F; Friess H
    Chirurg; 2020 May; 91(5):391-395. PubMed ID: 31965198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy for pancreatic cancer.
    Springfeld C; Jäger D; Büchler MW; Strobel O; Hackert T; Palmer DH; Neoptolemos JP
    Presse Med; 2019 Mar; 48(3 Pt 2):e159-e174. PubMed ID: 30879894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
    Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Clinical Trials in Pancreatic Cancer.
    Goel N; Reddy SS
    Surg Oncol Clin N Am; 2017 Oct; 26(4):767-790. PubMed ID: 28923230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review.
    Mavros MN; Moris D; Karanicolas PJ; Katz MHG; O'Reilly EM; Pawlik TM
    JAMA Surg; 2021 Jul; 156(7):663-672. PubMed ID: 33787841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of adjuvant therapy for pancreatic cancer.
    Katz MH; Fleming JB; Lee JE; Pisters PW
    Oncologist; 2010; 15(11):1205-13. PubMed ID: 21045189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of neoadjuvant gemcitabine plus S-1 and radiation therapy for borderline resectable pancreatic cancer.
    Yabushita Y; Matsuyama R; Miyake K; Homma Y; Kumamoto T; Misumi T; Hata M; Yamanaka S; Fujii S; Endo I
    J Hepatobiliary Pancreat Sci; 2023 Apr; 30(4):493-502. PubMed ID: 36178433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma.
    Motoi F; Unno M
    Jpn J Clin Oncol; 2020 May; 50(5):483-489. PubMed ID: 32083290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma.
    Sohal DPS
    Chin Clin Oncol; 2017 Jun; 6(3):26. PubMed ID: 28705003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.
    Labori KJ; Lassen K; Hoem D; Grønbech JE; Søreide JA; Mortensen K; Smaaland R; Sorbye H; Verbeke C; Dueland S
    BMC Surg; 2017 Aug; 17(1):94. PubMed ID: 28841916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
    Hintz B; Lee VJ
    JAMA Oncol; 2023 Feb; 9(2):277. PubMed ID: 36454584
    [No Abstract]   [Full Text] [Related]  

  • 15. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
    Grossberg AJ; Jethwa KR; Ellsworth SG
    JAMA Oncol; 2023 Feb; 9(2):275. PubMed ID: 36454560
    [No Abstract]   [Full Text] [Related]  

  • 16. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
    Dincer N; Ugurluer G; Ozyar E
    JAMA Oncol; 2023 Feb; 9(2):276-277. PubMed ID: 36454557
    [No Abstract]   [Full Text] [Related]  

  • 17. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
    Hall WA; Evans DB; Tsai S
    JAMA Oncol; 2023 Feb; 9(2):275-276. PubMed ID: 36454556
    [No Abstract]   [Full Text] [Related]  

  • 18. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply.
    Katz MHG; Herman JM; O'Reilly EM
    JAMA Oncol; 2023 Feb; 9(2):277-278. PubMed ID: 36454565
    [No Abstract]   [Full Text] [Related]  

  • 19. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
    Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
    Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
    Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
    JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.